Research programme: GyrB/ParE inhibitors - Vaxart
Latest Information Update: 16 Feb 2018
At a glance
- Originator Biota Pharmaceuticals
- Developer Aviragen Therapeutics
- Class
- Mechanism of Action DNA gyrase inhibitors; DNA topoisomerase IV inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Bacterial infections
Most Recent Events
- 13 Feb 2018 Aviragen Therapeutics has merged with Vaxart forming Vaxart
- 16 Jul 2016 No recent reports of development identified for preclinical development in Bacterial-infections in USA (IV)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Bacterial-infections in USA (PO)